FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements

Bulletin Express04-21

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the company’s website (www.fosunpharma.com) and on HKEX’s website (www.hkexnews.hk).

Registered shareholders who previously chose printed materials will receive hard-copy reports with this mailing. Shareholders preferring hard copies going forward can submit the enclosed reply form to the company’s Hong Kong H-share registrar, Tricor Investor Services Limited, using the prepaid mailing label or by email to is-ecom@vistra.com. FOSUN PHARMA will dispatch requested printed versions free of charge.

The company emphasizes the importance of maintaining a valid email address to receive electronic notifications of future corporate communications and actionable documents. Shareholders who have not provided, or need to update, an email address are urged to complete and return the reply form.

Enquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.-6:00 p.m. (excluding public holidays).

The notice was issued under the authority of the Board and signed by Chairman Mr. Chen Yuqing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197000659?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197000659","market":"us","top_or_hot":-1,"title":"FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the company’s website (www.fosunpharma.com) and on HKEX’s website (www.hkexnews.hk).</p>\n<p>Registered shareholders who previously chose printed materials will receive hard-copy reports with this mailing. Shareholders preferring hard copies going forward can submit the enclosed reply form to the company’s Hong Kong H-share registrar, Tricor Investor Services Limited, using the prepaid mailing label or by email to is-ecom@vistra.com. FOSUN PHARMA will dispatch requested printed versions free of charge.</p>\n<p>The company emphasizes the importance of maintaining a valid email address to receive electronic notifications of future corporate communications and actionable documents. Shareholders who have not provided, or need to update, an email address are urged to complete and return the reply form.</p>\n<p>Enquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.-6:00 p.m. (excluding public holidays).</p>\n<p>The notice was issued under the authority of the Board and signed by Chairman Mr. Chen Yuqing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-21 16:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the company’s website (www.fosunpharma.com) and on HKEX’s website (www.hkexnews.hk).</p>\n<p>Registered shareholders who previously chose printed materials will receive hard-copy reports with this mailing. Shareholders preferring hard copies going forward can submit the enclosed reply form to the company’s Hong Kong H-share registrar, Tricor Investor Services Limited, using the prepaid mailing label or by email to is-ecom@vistra.com. FOSUN PHARMA will dispatch requested printed versions free of charge.</p>\n<p>The company emphasizes the importance of maintaining a valid email address to receive electronic notifications of future corporate communications and actionable documents. Shareholders who have not provided, or need to update, an email address are urged to complete and return the reply form.</p>\n<p>Enquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.-6:00 p.m. (excluding public holidays).</p>\n<p>The notice was issued under the authority of the Board and signed by Chairman Mr. Chen Yuqing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1197000659","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197000659","pubTimestamp":1776761024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药宣布发布2025年年报并更新股东沟通安排","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FOSUN PHARMA) released a notification on 21 April 2026 confirming that its 2025 Annual Report is now available in both English and Chinese on the company’s website (www.fosunpharma.com) and on HKEX’s website (www.hkexnews.hk).\nRegistered shareholders who previously chose printed materials will receive hard-copy reports with this mailing. Shareholders preferring hard copies going forward can submit the enclosed reply form to the company’s Hong Kong H-share registrar, Tricor Investor Services Limited, using the prepaid mailing label or by email to is-ecom@vistra.com. FOSUN PHARMA will dispatch requested printed versions free of charge.\nThe company emphasizes the importance of maintaining a valid email address to receive electronic notifications of future corporate communications and actionable documents. Shareholders who have not provided, or need to update, an email address are urged to complete and return the reply form.\nEnquiries can be directed to Tricor’s hotline at (852) 2980 1333, Monday to Friday, 9:00 a.m.-6:00 p.m. (excluding public holidays).\nThe notice was issued under the authority of the Board and signed by Chairman Mr. Chen Yuqing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197000659","isCrawlerRequest":true}